2021年CUA和CUOG指南:去势抵抗性前列腺癌(CRPC)的管理

2021-02-10 加拿大泌尿外科协会 Can Urol Assoc J . 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.

2021年加拿大泌尿外科协会(CUA)-加拿大泌尿肿瘤学小组(CUOG)指南:去势抵抗性前列腺癌(CRPC)的管理

中文标题:

2021年CUA和CUOG指南:去势抵抗性前列腺癌(CRPC)的管理

发布机构:

加拿大泌尿外科协会

发布日期:

2021-02-10

简要介绍:

2021年加拿大泌尿外科协会(CUA)-加拿大泌尿肿瘤学小组(CUOG)指南:去势抵抗性前列腺癌(CRPC)的管理

相关资料下载:
[AttachmentFileName(sort=1, fileName=7074-Article Text-35534-1-10-20210201.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b94f51c002053ede, title=2021年CUA和CUOG指南:去势抵抗性前列腺癌(CRPC)的管理 , enTitle=, guiderFrom=Can Urol Assoc J . 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074., authorId=0, author=, summary=2021年加拿大泌尿外科协会(CUA)-加拿大泌尿肿瘤学小组(CUOG)指南:去势抵抗性前列腺癌(CRPC)的管理, cover=, journalId=0, articlesId=null, associationId=1160, associationName=加拿大泌尿外科协会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Feb 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b ChMk0b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">2021年加拿大泌尿外科协会(CUA)-加拿大泌尿肿瘤学小组(CUOG)指南:去势抵抗性前列腺癌(CRPC)的管理</span></span></p>, tagList=[TagDto(tagId=781, tagName=前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5291, appHits=110, showAppHits=0, pcHits=912, showPcHits=5181, likes=0, shares=6, comments=4, approvalStatus=1, publishedTime=Wed Feb 10 19:31:41 CST 2021, publishedTimeString=2021-02-10, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Wed Feb 10 19:31:36 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 22:54:02 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=7074-Article Text-35534-1-10-20210201.pdf)])
7074-Article Text-35534-1-10-20210201.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1005350, encodeId=78f510053500f, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Thu Aug 05 13:26:24 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967332, encodeId=d3df96e332d9, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:17:42 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967327, encodeId=adfd96e32742, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:14:21 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924236, encodeId=450d92423628, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:43 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-08-05 ms4000002095488795

    点赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1005350, encodeId=78f510053500f, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Thu Aug 05 13:26:24 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967332, encodeId=d3df96e332d9, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:17:42 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967327, encodeId=adfd96e32742, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:14:21 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924236, encodeId=450d92423628, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:43 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-05-20 ms8000000769818805

    分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1005350, encodeId=78f510053500f, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Thu Aug 05 13:26:24 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967332, encodeId=d3df96e332d9, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:17:42 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967327, encodeId=adfd96e32742, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:14:21 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924236, encodeId=450d92423628, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:43 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-05-20 ms8000000769818805

    点赞

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1005350, encodeId=78f510053500f, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Thu Aug 05 13:26:24 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967332, encodeId=d3df96e332d9, content=分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:17:42 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967327, encodeId=adfd96e32742, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc905505382, createdName=ms8000000769818805, createdTime=Thu May 20 22:14:21 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924236, encodeId=450d92423628, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Fri Feb 12 07:46:43 CST 2021, time=2021-02-12, status=1, ipAttribution=)]
    2021-02-12 carrotlyl

    感谢分享

    0